Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathew P Leese

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Cancer Research|January 7, 2006
The role of 17beta-hydroxysteroid dehydrogenases in modulating the activity of 2-methoxyestradiol in breast cancer cellsSimon P Newman, Christopher R Ireson, Helena J Tutill, et al.
Journal of Medicinal Chemistry|December 22, 2006
2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activityMathew P Leese, Bertrand Leblond, Andrew Smith, et al.
Chemmedchem|March 6, 2014
Synthesis, anti-tubulin and antiproliferative SAR of steroidomimetic dihydroisoquinolinonesMathew P Leese, Fabrice L Jourdan, Meriel R Major, et al.
Journal of Medicinal Chemistry|August 19, 2007
3,17-disubstituted 2-alkylestra-1,3,5(10)-trien-3-ol derivatives: synthesis, in vitro and in vivo anticancer activityChristian Bubert, Mathew P Leese, Mary F Mahon, et al.
Anticancer Research|May 30, 2008
A new micronized formulation of 2-methoxyestradiol-bis-sulfamate (STX140) is therapeutically potent against breast cancerPaul A Foster, Simon P Newman, Mathew P Leese, et al.
Chemmedchem|January 18, 2014
Synthesis, antitubulin, and antiproliferative SAR of C3/C1-substituted tetrahydroisoquinolinesWolfgang Dohle, Mathew P Leese, Fabrice L Jourdan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2008
STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cellsSimon P Newman, Paul A Foster, Chloe Stengel, et al.
British Journal of Cancer|October 14, 2015
Targeted NF1 cancer therapeutics with multiple modes of action: small molecule hormone-like agents resembling the natural anticancer metabolite, 2-methoxyoestradiolYu-chi Shen, Ravi Upadhyayula, Stephanie Cevallos, et al.
Journal of Medicinal Chemistry|December 12, 2017
Quinazolinone-Based Anticancer Agents: Synthesis, Antiproliferative SAR, Antitubulin Activity, and Tubulin Co-crystal StructureWolfgang Dohle, Fabrice L Jourdan, Grégory Menchon, et al.
Chemical Communications (Cambridge, England)|April 14, 2010
Chimeric microtubule disruptorsMathew P Leese, Fabrice Jourdan, Meriel R Kimberley, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Cancer Research|January 7, 2006
The role of 17beta-hydroxysteroid dehydrogenases in modulating the activity of 2-methoxyestradiol in breast cancer cellsSimon P Newman, Christopher R Ireson, Helena J Tutill, et al.
Journal of Medicinal Chemistry|December 22, 2006
2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activityMathew P Leese, Bertrand Leblond, Andrew Smith, et al.
Chemmedchem|March 6, 2014
Synthesis, anti-tubulin and antiproliferative SAR of steroidomimetic dihydroisoquinolinonesMathew P Leese, Fabrice L Jourdan, Meriel R Major, et al.
Journal of Medicinal Chemistry|August 19, 2007
3,17-disubstituted 2-alkylestra-1,3,5(10)-trien-3-ol derivatives: synthesis, in vitro and in vivo anticancer activityChristian Bubert, Mathew P Leese, Mary F Mahon, et al.
Anticancer Research|May 30, 2008
A new micronized formulation of 2-methoxyestradiol-bis-sulfamate (STX140) is therapeutically potent against breast cancerPaul A Foster, Simon P Newman, Mathew P Leese, et al.
Chemmedchem|January 18, 2014
Synthesis, antitubulin, and antiproliferative SAR of C3/C1-substituted tetrahydroisoquinolinesWolfgang Dohle, Mathew P Leese, Fabrice L Jourdan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2008
STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cellsSimon P Newman, Paul A Foster, Chloe Stengel, et al.
British Journal of Cancer|October 14, 2015
Targeted NF1 cancer therapeutics with multiple modes of action: small molecule hormone-like agents resembling the natural anticancer metabolite, 2-methoxyoestradiolYu-chi Shen, Ravi Upadhyayula, Stephanie Cevallos, et al.
Journal of Medicinal Chemistry|December 12, 2017
Quinazolinone-Based Anticancer Agents: Synthesis, Antiproliferative SAR, Antitubulin Activity, and Tubulin Co-crystal StructureWolfgang Dohle, Fabrice L Jourdan, Grégory Menchon, et al.
Chemical Communications (Cambridge, England)|April 14, 2010
Chimeric microtubule disruptorsMathew P Leese, Fabrice Jourdan, Meriel R Kimberley, et al.
Pageof 4